Please provide your email address to receive an email when new articles are posted on . The FDA expanded the indication for Tremfya (guselkumab) to children with plaque psoriasis or active psoriatic ...

Tremfya is the first IL-23 inhibitor approved for pediatric plaque psoriasis and psoriatic arthritis, based on the PROTOSTAR trial's positive results. The PROTOSTAR trial demonstrated significant skin ...

In the Mediterranean diet group, 47.4% achieved a 75% reduction in PASI compared with 0% in the control group. HealthDay News — A 16-week Mediterranean diet intervention significantly improves ...

Psoriasis may not have a cure, but new research has found that significant relief could be achieved at the dinner table. In a clinical trial, scientists found that a Mediterranean diet could ...

Over 60 million people worldwide are affected by psoriasis, a chronic inflammatory skin disorder that causes red, scaly patches and persistent itching. A new study has found that following a ...

The Mediterranean diet may improve psoriasis through multiple metabolic and molecular pathways relevant to chronic inflammation. In this randomized trial, following a Mediterranean diet significantly ...

GLP-1 agonists appeared to have a bigger impact on the physical and mental health of patients with psoriasis compared with other patients, a large retrospective cohort study showed. Reductions in ...

Please provide your email address to receive an email when new articles are posted on . Older adults with psoriasis are more likely to develop macular degeneration. Biologic use may lower macular ...

Psoriasis patients taking GLP-1 drugs had a 78% lower risk of premature death and a 44% lower risk of heart attack, stroke or other heart-related health crisis, researchers reported Thursday at a ...

People with psoriasis might receive unexpected benefits from cutting-edge weight loss drugs like Ozempic and Zepbound, a new study says. Psoriasis patients taking GLP-1 drugs had a 78% lower risk of ...

Sept 17 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's (BMY.N), opens new ...

"Psoriasis is a systemic inflammatory disease in which lipid dysregulation contributes to cardiovascular disease," explained Dr. Treichel. "Because abnormal lipid deposition in the retina is a ...